MORE: Biogen Falls 9% After Anti-LINGO Misses Study Endpoints
Source: BFW (Bloomberg First Word)
Tickers
BIIB US (Biogen Inc)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Biogen trades as low as $262 on pre-market vol. >20k shares.
Alert: HALISTER- Says opicinumab (anti-LINGO-1) missed primary endpoint evaluating physical function, cognitive function and disability in Phase 2 multiple sclerosis study.
- BIIB says evidence of clinical effect seen with complex, unexpected dose-response
- Opicinumab also missed secondary endpoints evaluating slowing of disability progression
- BIIB continues to analyze results to inform design of next study
- NOTE: Anti-LINGO one of key drugs in BIIB’s pipeline
- April 14, Biogen’s Anti-Lingo-1 Benefit Persists in 32- Week Data: Study Link
Source: BFW (Bloomberg First Word)
Tickers
BIIB US (Biogen Inc)
To de-activate this alert, click here
UUID: 7947283